How ten23 health is Advancing Patient-Centric Drug Delivery

CEO of the Year finalist at 2025 CPHI Pharma Awards, Prof. Dr. Mahler Hanns-Christian, who serves as CEO and co-founder of ten23 health, explains how ten23 health is helping shape the future of patient-centric drug delivery systems and the evolving expectations of modern CDMOs. He shares how industry limitations—particularly around flexibility, innovation, and patient-focused design—motivated him to co-found the company and build a new model for sterile drug product development and manufacturing.

Prof. Dr. Hanns-Christian comments on the growing demand for subcutaneous and self-injection therapies, highlighting why ease of use, patient comfort, and real-world administration are becoming central considerations in formulation and device design. He also explains how CDMOs can better support pharma partners by integrating delivery-system thinking early in development, strengthening supply chain reliability, and offering high-quality testing and sterile manufacturing capabilities at scale.

Sustainability is another major theme of the conversation. He outlines how next-generation CDMOs can embed responsible operations, energy efficiency, and waste reduction into everyday decision-making—advancing both environmental goals and long-term business resilience.

Looking ahead, Prof. Dr. Hanns-Christian shares what excites him most about the future: expanded manufacturing capacity, continued innovation in patient-centric delivery, and new opportunities to elevate quality, reliability, and patient outcomes across the drug product lifecycle.